Overview
Cebranopadol is a synthetic analgesic compound developed as a dual agonist targeting both the nociceptin/orphanin FQ peptide (NOP) receptor and the μ-opioid receptor (MOR). It represents a new class of pain relievers designed to address the limitations of traditional opioids, such as addiction and respiratory depression. Cebranopadol is currently under clinical investigation for its efficacy in managing chronic pain conditions, including neuropathic pain and osteoarthritis. Research suggests that cebranopadol's dual mechanism of action may provide superior pain relief with fewer side effects compared to conventional opioids. Its development aligns with the growing demand for safer and more effective analgesics in the pharmaceutical industry.
Physical and Chemical Properties
Cebranopadol is characterized by its white to off-white powder appearance and a molecular weight of 392.49 g/mol. It is soluble in organic solvents like DMSO and ethanol, which facilitates its formulation into various pharmaceutical products. The compound's dual agonist activity at NOP and MOR receptors underpins its pharmacological profile, offering high potency and selectivity. The exact melting and boiling points of cebranopadol are not widely documented, but it is known to be stable under standard storage conditions. Proper handling is essential to maintain its integrity, as exposure to light and moisture may degrade the compound.
Main Applications
Cebranopadol is primarily investigated for its potential in treating moderate to severe chronic pain, including conditions like neuropathic pain and osteoarthritis. Its dual agonist activity at NOP and MOR receptors may provide a broader therapeutic window compared to traditional opioids, reducing the risk of addiction and respiratory depression. In addition to chronic pain management, cebranopadol is being explored for its efficacy in other pain-related conditions, such as fibromyalgia and postoperative pain. Its unique mechanism of action makes it a promising candidate for future pain therapies, particularly in patients who do not respond well to existing treatments.
Safety and Storage
Cebranopadol should be handled with care to avoid inhalation or skin contact, as it may cause dizziness or drowsiness. Proper personal protective equipment, such as gloves and lab coats, is recommended when working with this compound. Storage conditions should include a cool, dry place, protected from light and moisture to maintain stability. While cebranopadol is under clinical investigation, its safety profile appears favorable compared to traditional opioids. However, further studies are needed to fully understand its long-term effects and potential risks. Regulatory compliance is essential for procurement and use in research or pharmaceutical development.
B2B Procurement Guide
When procuring cebranopadol, B2B buyers should prioritize suppliers who adhere to strict regulatory standards and provide certificates of analysis. This ensures the compound's purity and compliance with pharmaceutical requirements. Prices may vary based on quantity and supplier, so obtaining multiple quotes is advisable. Buyers should also consider the compound's storage and handling requirements to prevent degradation during transit. Establishing a reliable supply chain is critical for ongoing research or production needs. Collaboration with reputable suppliers can mitigate risks and ensure consistent quality.